-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
Beihaikang made a global offering of 56,251,000 shares at a final issue price of HK$12.
In this IPO, a total of seven well-known cornerstone investors participated, including RA Capital, Hudson Bay Master Fund Ltd.
Beihai Kangcheng is a Chinese biomedical company focusing on rare diseases.
The product pipeline of Beihai Kangcheng consists of 13 drugs, all of which have huge market potential.
The company’s core product, CAN008, is a glycosylated CD95 Fc fusion protein for the treatment of GBM.
"Listing on the Hong Kong Stock Exchange is a major milestone for Beihai Kangcheng.
About Beihai Kangcheng
Beihai Kangcheng Pharmaceutical Co.
Beihai Kangcheng currently has a comprehensive and differentiated pipeline consisting of 13 pharmaceutical assets with huge market potential, targeting some of the most common rare diseases and rare tumor indications
Beihai Kangcheng strategically combines global cooperation and domestic research to establish and enrich its drug portfolio, while investing in the next generation of gene therapy technology for rare disease treatment
For more information about Beihai Kangcheng Pharmaceutical Co.